MGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MacroGenics Inc (MGNX) is not a good buy for a beginner investor with a long-term strategy at this time. The recent clinical hold on a critical trial, significant financial underperformance, and lack of strong positive catalysts outweigh the technical indicators suggesting short-term bullish momentum. The stock carries high risks, and there are no clear signs of recovery or long-term growth potential.
The stock shows short-term bullish momentum with a positive MACD histogram (0.0179) and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the RSI_6 at 82.393 indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at R1: 1.944 and R2: 2.041, while support levels are at S1: 1.631 and S2: 1.534.
The stock is showing short-term bullish technical indicators, and the company is actively working with the FDA to resolve the clinical hold.
The FDA's partial clinical hold on the LINNET trial due to safety concerns, including serious adverse effects and one death, has significantly impacted investor confidence. Additionally, the company's financial performance in 2025/Q3 showed a sharp decline in revenue (-34.21% YoY), net income (-70.13% YoY), and EPS (-70.00% YoY).
In 2025/Q3, MacroGenics reported a significant decline in revenue to $72.84M (-34.21% YoY), net income to $16.82M (-70.13% YoY), and EPS to 0.27 (-70.00% YoY). Gross margin also dropped to 84.09 (-14.46% YoY), indicating worsening profitability.
No data available for analyst ratings or price target changes.
